Zydus Lifesciences down, Nuvama downgrades stock despite a strong Q1

Nuvama downgrades Zydus to ‘hold’. It says Q1 results are unlikely to be repeated, as exclusivity of epilepsy drug Trokendi is declining and revenue from blood cancer drug Revlimid remains #39;lumpy#39;
http://dlvr.it/StcTr5